Table of Content

1 Neurodegenerative Drugs Market Overview
1.1 Product Overview and Scope of Neurodegenerative Drugs
1.2 Neurodegenerative Drugs Segment by Type
1.2.1 Global Neurodegenerative Drugs Market Value Comparison by Type (2024-2034)
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Neurodegenerative Drugs Segment by Application
1.3.1 Global Neurodegenerative Drugs Market Value by Application: (2024-2034)
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Global Neurodegenerative Drugs Market Size Estimates and Forecasts
1.4.1 Global Neurodegenerative Drugs Revenue 2018-2029
1.4.2 Global Neurodegenerative Drugs Sales 2018-2029
1.4.3 Global Neurodegenerative Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Neurodegenerative Drugs Market Competition by Manufacturers
2.1 Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2018-2024)
2.2 Global Neurodegenerative Drugs Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Neurodegenerative Drugs Average Price by Manufacturers (2018-2024)
2.4 Global Neurodegenerative Drugs Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Neurodegenerative Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neurodegenerative Drugs, Product Type & Application
2.7 Neurodegenerative Drugs Market Competitive Situation and Trends
2.7.1 Neurodegenerative Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neurodegenerative Drugs Players Market Share by Revenue
2.7.3 Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neurodegenerative Drugs Retrospective Market Scenario by Region
3.1 Global Neurodegenerative Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Neurodegenerative Drugs Global Neurodegenerative Drugs Sales by Region: 2018-2029
3.2.1 Global Neurodegenerative Drugs Sales by Region: 2018-2024
3.2.2 Global Neurodegenerative Drugs Sales by Region: 2024-2029
3.3 Global Neurodegenerative Drugs Global Neurodegenerative Drugs Revenue by Region: 2018-2029
3.3.1 Global Neurodegenerative Drugs Revenue by Region: 2018-2024
3.3.2 Global Neurodegenerative Drugs Revenue by Region: 2024-2029
3.4 North America Neurodegenerative Drugs Market Facts & Figures by Country
3.4.1 North America Neurodegenerative Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Neurodegenerative Drugs Sales by Country (2018-2029)
3.4.3 North America Neurodegenerative Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Neurodegenerative Drugs Market Facts & Figures by Country
3.5.1 Europe Neurodegenerative Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Neurodegenerative Drugs Sales by Country (2018-2029)
3.5.3 Europe Neurodegenerative Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurodegenerative Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Neurodegenerative Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Neurodegenerative Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Neurodegenerative Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Neurodegenerative Drugs Market Facts & Figures by Country
3.7.1 Latin America Neurodegenerative Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Neurodegenerative Drugs Sales by Country (2018-2029)
3.7.3 Latin America Neurodegenerative Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurodegenerative Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Neurodegenerative Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Neurodegenerative Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neurodegenerative Drugs Sales by Type (2018-2029)
4.1.1 Global Neurodegenerative Drugs Sales by Type (2018-2024)
4.1.2 Global Neurodegenerative Drugs Sales by Type (2024-2029)
4.1.3 Global Neurodegenerative Drugs Sales Market Share by Type (2018-2029)
4.2 Global Neurodegenerative Drugs Revenue by Type (2018-2029)
4.2.1 Global Neurodegenerative Drugs Revenue by Type (2018-2024)
4.2.2 Global Neurodegenerative Drugs Revenue by Type (2024-2029)
4.2.3 Global Neurodegenerative Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Neurodegenerative Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Neurodegenerative Drugs Sales by Application (2018-2029)
5.1.1 Global Neurodegenerative Drugs Sales by Application (2018-2024)
5.1.2 Global Neurodegenerative Drugs Sales by Application (2024-2029)
5.1.3 Global Neurodegenerative Drugs Sales Market Share by Application (2018-2029)
5.2 Global Neurodegenerative Drugs Revenue by Application (2018-2029)
5.2.1 Global Neurodegenerative Drugs Revenue by Application (2018-2024)
5.2.2 Global Neurodegenerative Drugs Revenue by Application (2024-2029)
5.2.3 Global Neurodegenerative Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Neurodegenerative Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Novartis Neurodegenerative Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Pfizer Neurodegenerative Drugs Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Merck Serono
6.3.1 Merck Serono Corporation Information
6.3.2 Merck Serono Description and Business Overview
6.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Merck Serono Neurodegenerative Drugs Product Portfolio
6.3.5 Merck Serono Recent Developments/Updates
6.4 Biogen Idec
6.4.1 Biogen Idec Corporation Information
6.4.2 Biogen Idec Description and Business Overview
6.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Biogen Idec Neurodegenerative Drugs Product Portfolio
6.4.5 Biogen Idec Recent Developments/Updates
6.5 TEVA
6.5.1 TEVA Corporation Information
6.5.2 TEVA Description and Business Overview
6.5.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.5.4 TEVA Neurodegenerative Drugs Product Portfolio
6.5.5 TEVA Recent Developments/Updates
6.6 UCB
6.6.1 UCB Corporation Information
6.6.2 UCB Description and Business Overview
6.6.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.6.4 UCB Neurodegenerative Drugs Product Portfolio
6.6.5 UCB Recent Developments/Updates
6.7 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
6.7.5 Boehringer Ingelheim Recent Developments/Updates
6.8 Sanofi
6.8.1 Sanofi Corporation Information
6.8.2 Sanofi Description and Business Overview
6.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Sanofi Neurodegenerative Drugs Product Portfolio
6.8.5 Sanofi Recent Developments/Updates
6.9 GlaxoSmithKline
6.9.1 GlaxoSmithKline Corporation Information
6.9.2 GlaxoSmithKline Description and Business Overview
6.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.9.4 GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
6.9.5 GlaxoSmithKline Recent Developments/Updates
6.10 Livzon Pharmaceutical
6.10.1 Livzon Pharmaceutical Corporation Information
6.10.2 Livzon Pharmaceutical Description and Business Overview
6.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.10.5 Livzon Pharmaceutical Recent Developments/Updates
6.11 Haisco Pharmaceutical
6.11.1 Haisco Pharmaceutical Corporation Information
6.11.2 Haisco Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.11.5 Haisco Pharmaceutical Recent Developments/Updates
6.12 Jingxin Pharmaceutical
6.12.1 Jingxin Pharmaceutical Corporation Information
6.12.2 Jingxin Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.12.5 Jingxin Pharmaceutical Recent Developments/Updates
6.13 Dongcheng Biochemicals
6.13.1 Dongcheng Biochemicals Corporation Information
6.13.2 Dongcheng Biochemicals Neurodegenerative Drugs Description and Business Overview
6.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
6.13.5 Dongcheng Biochemicals Recent Developments/Updates
6.14 Hisun Pharmaceutical
6.14.1 Hisun Pharmaceutical Corporation Information
6.14.2 Hisun Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.14.5 Hisun Pharmaceutical Recent Developments/Updates
6.15 Luye Pharma
6.15.1 Luye Pharma Corporation Information
6.15.2 Luye Pharma Neurodegenerative Drugs Description and Business Overview
6.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Luye Pharma Neurodegenerative Drugs Product Portfolio
6.15.5 Luye Pharma Recent Developments/Updates
6.16 Ark Pharmaceutical
6.16.1 Ark Pharmaceutical Corporation Information
6.16.2 Ark Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.16.4 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.16.5 Ark Pharmaceutical Recent Developments/Updates
6.17 Kanghong Pharmaceutical
6.17.1 Kanghong Pharmaceutical Corporation Information
6.17.2 Kanghong Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.17.5 Kanghong Pharmaceutical Recent Developments/Updates
6.18 Huahai Pharmaceutical
6.18.1 Huahai Pharmaceutical Corporation Information
6.18.2 Huahai Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.18.5 Huahai Pharmaceutical Recent Developments/Updates
6.19 BORA PHARMACEUTICALS
6.19.1 BORA PHARMACEUTICALS Corporation Information
6.19.2 BORA PHARMACEUTICALS Neurodegenerative Drugs Description and Business Overview
6.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
6.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
6.19.5 BORA PHARMACEUTICALS Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurodegenerative Drugs Industry Chain Analysis
7.2 Neurodegenerative Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurodegenerative Drugs Production Mode & Process
7.4 Neurodegenerative Drugs Sales and Marketing
7.4.1 Neurodegenerative Drugs Sales Channels
7.4.2 Neurodegenerative Drugs Distributors
7.5 Neurodegenerative Drugs Customers
8 Neurodegenerative Drugs Market Dynamics
8.1 Neurodegenerative Drugs Industry Trends
8.2 Neurodegenerative Drugs Market Drivers
8.3 Neurodegenerative Drugs Market Challenges
8.4 Neurodegenerative Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Neurodegenerative Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Neurodegenerative Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Neurodegenerative Drugs Market Competitive Situation by Manufacturers in 2022
Table 4. Global Neurodegenerative Drugs Sales (MT) of Key Manufacturers (2018-2024)
Table 5. Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Neurodegenerative Drugs Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Neurodegenerative Drugs Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Neurodegenerative Drugs Average Price (US$/MT) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Neurodegenerative Drugs, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Neurodegenerative Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Neurodegenerative Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Neurodegenerative Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Neurodegenerative Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Drugs as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Neurodegenerative Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Neurodegenerative Drugs Sales by Region (2018-2024) & (MT)
Table 18. Global Neurodegenerative Drugs Sales Market Share by Region (2018-2024)
Table 19. Global Neurodegenerative Drugs Sales by Region (2024-2029) & (MT)
Table 20. Global Neurodegenerative Drugs Sales Market Share by Region (2024-2029)
Table 21. Global Neurodegenerative Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Neurodegenerative Drugs Revenue Market Share by Region (2018-2024)
Table 23. Global Neurodegenerative Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Neurodegenerative Drugs Revenue Market Share by Region (2024-2029)
Table 25. North America Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 27. North America Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 28. North America Neurodegenerative Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Neurodegenerative Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 32. Europe Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 33. Europe Neurodegenerative Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Neurodegenerative Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Neurodegenerative Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Neurodegenerative Drugs Sales by Region (2018-2024) & (MT)
Table 37. Asia Pacific Neurodegenerative Drugs Sales by Region (2024-2029) & (MT)
Table 38. Asia Pacific Neurodegenerative Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Neurodegenerative Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 42. Latin America Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 43. Latin America Neurodegenerative Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Neurodegenerative Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 47. Middle East & Africa Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 48. Middle East & Africa Neurodegenerative Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Neurodegenerative Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Neurodegenerative Drugs Sales (MT) by Type (2018-2024)
Table 51. Global Neurodegenerative Drugs Sales (MT) by Type (2024-2029)
Table 52. Global Neurodegenerative Drugs Sales Market Share by Type (2018-2024)
Table 53. Global Neurodegenerative Drugs Sales Market Share by Type (2024-2029)
Table 54. Global Neurodegenerative Drugs Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Neurodegenerative Drugs Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Neurodegenerative Drugs Revenue Market Share by Type (2018-2024)
Table 57. Global Neurodegenerative Drugs Revenue Market Share by Type (2024-2029)
Table 58. Global Neurodegenerative Drugs Price (US$/MT) by Type (2018-2024)
Table 59. Global Neurodegenerative Drugs Price (US$/MT) by Type (2024-2029)
Table 60. Global Neurodegenerative Drugs Sales (MT) by Application (2018-2024)
Table 61. Global Neurodegenerative Drugs Sales (MT) by Application (2024-2029)
Table 62. Global Neurodegenerative Drugs Sales Market Share by Application (2018-2024)
Table 63. Global Neurodegenerative Drugs Sales Market Share by Application (2024-2029)
Table 64. Global Neurodegenerative Drugs Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Neurodegenerative Drugs Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Neurodegenerative Drugs Revenue Market Share by Application (2018-2024)
Table 67. Global Neurodegenerative Drugs Revenue Market Share by Application (2024-2029)
Table 68. Global Neurodegenerative Drugs Price (US$/MT) by Application (2018-2024)
Table 69. Global Neurodegenerative Drugs Price (US$/MT) by Application (2024-2029)
Table 70. Novartis Corporation Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 73. Novartis Neurodegenerative Drugs Product
Table 74. Novartis Recent Developments/Updates
Table 75. Pfizer Corporation Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 78. Pfizer Neurodegenerative Drugs Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Merck Serono Corporation Information
Table 81. Merck Serono Description and Business Overview
Table 82. Merck Serono Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 83. Merck Serono Neurodegenerative Drugs Product
Table 84. Merck Serono Recent Developments/Updates
Table 85. Biogen Idec Corporation Information
Table 86. Biogen Idec Description and Business Overview
Table 87. Biogen Idec Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 88. Biogen Idec Neurodegenerative Drugs Product
Table 89. Biogen Idec Recent Developments/Updates
Table 90. TEVA Corporation Information
Table 91. TEVA Description and Business Overview
Table 92. TEVA Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 93. TEVA Neurodegenerative Drugs Product
Table 94. TEVA Recent Developments/Updates
Table 95. UCB Corporation Information
Table 96. UCB Description and Business Overview
Table 97. UCB Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 98. UCB Neurodegenerative Drugs Product
Table 99. UCB Recent Developments/Updates
Table 100. Boehringer Ingelheim Corporation Information
Table 101. Boehringer Ingelheim Description and Business Overview
Table 102. Boehringer Ingelheim Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 103. Boehringer Ingelheim Neurodegenerative Drugs Product
Table 104. Boehringer Ingelheim Recent Developments/Updates
Table 105. Sanofi Corporation Information
Table 106. Sanofi Description and Business Overview
Table 107. Sanofi Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 108. Sanofi Neurodegenerative Drugs Product
Table 109. Sanofi Recent Developments/Updates
Table 110. GlaxoSmithKline Corporation Information
Table 111. GlaxoSmithKline Description and Business Overview
Table 112. GlaxoSmithKline Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 113. GlaxoSmithKline Neurodegenerative Drugs Product
Table 114. GlaxoSmithKline Recent Developments/Updates
Table 115. Livzon Pharmaceutical Corporation Information
Table 116. Livzon Pharmaceutical Description and Business Overview
Table 117. Livzon Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 118. Livzon Pharmaceutical Neurodegenerative Drugs Product
Table 119. Livzon Pharmaceutical Recent Developments/Updates
Table 120. Haisco Pharmaceutical Corporation Information
Table 121. Haisco Pharmaceutical Description and Business Overview
Table 122. Haisco Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 123. Haisco Pharmaceutical Neurodegenerative Drugs Product
Table 124. Haisco Pharmaceutical Recent Developments/Updates
Table 125. Jingxin Pharmaceutical Corporation Information
Table 126. Jingxin Pharmaceutical Description and Business Overview
Table 127. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 128. Jingxin Pharmaceutical Neurodegenerative Drugs Product
Table 129. Jingxin Pharmaceutical Recent Developments/Updates
Table 130. Dongcheng Biochemicals Corporation Information
Table 131. Dongcheng Biochemicals Description and Business Overview
Table 132. Dongcheng Biochemicals Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 133. Dongcheng Biochemicals Neurodegenerative Drugs Product
Table 134. Dongcheng Biochemicals Recent Developments/Updates
Table 135. Hisun Pharmaceutical Corporation Information
Table 136. Hisun Pharmaceutical Description and Business Overview
Table 137. Hisun Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 138. Hisun Pharmaceutical Neurodegenerative Drugs Product
Table 139. Hisun Pharmaceutical Recent Developments/Updates
Table 140. Luye Pharma Corporation Information
Table 141. Luye Pharma Description and Business Overview
Table 142. Luye Pharma Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 143. Luye Pharma Neurodegenerative Drugs Product
Table 144. Luye Pharma Recent Developments/Updates
Table 145. Ark Pharmaceutical Corporation Information
Table 146. Ark Pharmaceutical Description and Business Overview
Table 147. Ark Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 148. Ark Pharmaceutical Neurodegenerative Drugs Product
Table 149. Ark Pharmaceutical Recent Developments/Updates
Table 150. Kanghong Pharmaceutical Corporation Information
Table 151. Kanghong Pharmaceutical Description and Business Overview
Table 152. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 153. Kanghong Pharmaceutical Neurodegenerative Drugs Product
Table 154. Kanghong Pharmaceutical Recent Developments/Updates
Table 155. Huahai Pharmaceutical Corporation Information
Table 156. Huahai Pharmaceutical Description and Business Overview
Table 157. Huahai Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 158. Huahai Pharmaceutical Neurodegenerative Drugs Product
Table 159. Huahai Pharmaceutical Recent Developments/Updates
Table 160. BORA PHARMACEUTICALS Corporation Information
Table 161. BORA PHARMACEUTICALS Description and Business Overview
Table 162. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 163. BORA PHARMACEUTICALS Neurodegenerative Drugs Product
Table 164. BORA PHARMACEUTICALS Recent Developments/Updates
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Neurodegenerative Drugs Distributors List
Table 168. Neurodegenerative Drugs Customers List
Table 169. Neurodegenerative Drugs Market Trends
Table 170. Neurodegenerative Drugs Market Drivers
Table 171. Neurodegenerative Drugs Market Challenges
Table 172. Neurodegenerative Drugs Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Neurodegenerative Drugs
Figure 2. Global Neurodegenerative Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Neurodegenerative Drugs Market Share by Type in 2022 & 2029
Figure 4. NMDA Product Picture
Figure 5. SSRIs Product Picture
Figure 6. Dopamine Inhibitors Product Picture
Figure 7. Global Neurodegenerative Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Neurodegenerative Drugs Market Share by Application in 2022 & 2029
Figure 9. Parkinson’s Disease
Figure 10. Huntington Disease
Figure 11. Amyotrophic Lateral Sclerosis
Figure 12. Alzheimer’s Disease
Figure 13. Global Neurodegenerative Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Neurodegenerative Drugs Market Size (2018-2029) & (US$ Million)
Figure 15. Global Neurodegenerative Drugs Sales (2018-2029) & (MT)
Figure 16. Global Neurodegenerative Drugs Average Price (US$/MT) & (2018-2029)
Figure 17. Neurodegenerative Drugs Report Years Considered
Figure 18. Neurodegenerative Drugs Sales Share by Manufacturers in 2022
Figure 19. Global Neurodegenerative Drugs Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest Neurodegenerative Drugs Players: Market Share by Revenue in 2022
Figure 21. Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 22. Global Neurodegenerative Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 23. North America Neurodegenerative Drugs Sales Market Share by Country (2018-2029)
Figure 24. North America Neurodegenerative Drugs Revenue Market Share by Country (2018-2029)
Figure 25. United States Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Canada Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Europe Neurodegenerative Drugs Sales Market Share by Country (2018-2029)
Figure 28. Europe Neurodegenerative Drugs Revenue Market Share by Country (2018-2029)
Figure 29. Germany Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. France Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. U.K. Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Italy Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Russia Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Asia Pacific Neurodegenerative Drugs Sales Market Share by Region (2018-2029)
Figure 35. Asia Pacific Neurodegenerative Drugs Revenue Market Share by Region (2018-2029)
Figure 36. China Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Japan Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. South Korea Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. India Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Australia Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. China Taiwan Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Indonesia Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Thailand Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Malaysia Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America Neurodegenerative Drugs Sales Market Share by Country (2018-2029)
Figure 46. Latin America Neurodegenerative Drugs Revenue Market Share by Country (2018-2029)
Figure 47. Mexico Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Neurodegenerative Drugs Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. UAE Neurodegenerative Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Neurodegenerative Drugs by Type (2018-2029)
Figure 56. Global Revenue Market Share of Neurodegenerative Drugs by Type (2018-2029)
Figure 57. Global Neurodegenerative Drugs Price (US$/MT) by Type (2018-2029)
Figure 58. Global Sales Market Share of Neurodegenerative Drugs by Application (2018-2029)
Figure 59. Global Revenue Market Share of Neurodegenerative Drugs by Application (2018-2029)
Figure 60. Global Neurodegenerative Drugs Price (US$/MT) by Application (2018-2029)
Figure 61. Neurodegenerative Drugs Value Chain
Figure 62. Neurodegenerative Drugs Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed